Skip to main content

Adenovirus-human HER2 vaccine inhibits breast cancer growth and vaccine induced antibodies (VIA) are efficacious against Herceptin-refractory human breast cancer

Publication ,  Journal Article
Wei, J; Hartman, Z; Osada, T; Yang, XY; Lei, G; Jiang, H; Chong, G; Amalfitano, A; Lyerly, HK; Morse, M; Clay, T
Published in: JOURNAL OF IMMUNOLOGY
April 1, 2007

Duke Scholars

Published In

JOURNAL OF IMMUNOLOGY

EISSN

1550-6606

ISSN

0022-1767

Publication Date

April 1, 2007

Volume

178

Publisher

AMER ASSOC IMMUNOLOGISTS

Related Subject Headings

  • Immunology
  • 3204 Immunology
  • 3101 Biochemistry and cell biology
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wei, J., Hartman, Z., Osada, T., Yang, X. Y., Lei, G., Jiang, H., … Clay, T. (2007). Adenovirus-human HER2 vaccine inhibits breast cancer growth and vaccine induced antibodies (VIA) are efficacious against Herceptin-refractory human breast cancer. JOURNAL OF IMMUNOLOGY, 178.
Wei, Junping, Zachary Hartman, Takuya Osada, Xiao Yi Yang, Gangjun Lei, Haixiang Jiang, Gabriel Chong, et al. “Adenovirus-human HER2 vaccine inhibits breast cancer growth and vaccine induced antibodies (VIA) are efficacious against Herceptin-refractory human breast cancer.” JOURNAL OF IMMUNOLOGY 178 (April 1, 2007).
Wei J, Hartman Z, Osada T, Yang XY, Lei G, Jiang H, Chong G, Amalfitano A, Lyerly HK, Morse M, Clay T. Adenovirus-human HER2 vaccine inhibits breast cancer growth and vaccine induced antibodies (VIA) are efficacious against Herceptin-refractory human breast cancer. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS; 2007 Apr 1;178.

Published In

JOURNAL OF IMMUNOLOGY

EISSN

1550-6606

ISSN

0022-1767

Publication Date

April 1, 2007

Volume

178

Publisher

AMER ASSOC IMMUNOLOGISTS

Related Subject Headings

  • Immunology
  • 3204 Immunology
  • 3101 Biochemistry and cell biology
  • 1107 Immunology